Lumbar disc disease is the drying out of the spongy interior matrix of an intervertebral disc in the spine. Many physicians and patients use the term lumber disc disease to encompass several different causes of back pain or sciatica. It is thought that lumber disc disease causes about one-third of all back pain. Pain, loss of muscle strength, and loss of touch sensation may occur if this herniation causes the compression of the most proximal part of the nerve closely neighboring the intervertebral disc material. Pain is in the distribution of the nerve compressed, usually down the back of the leg, side of the calf, and inside of the foot. Most commonly, the nerve root between the fifth lumbar vertebra and the first sacral segment is impinged. Disk degeneration typically develops in the parts of the spine that move the lower back and neck. Lumbar degenerative disk disease and cervical degenerative disk disease.
The goal is to ease pain and stop more damage. The treatment of chronic lumbar disc disease medication includes over-the-counter pain relievers like aspirin and ibuprofen can help fight inflammation. They can ease pain and lessen swelling. Physical therapy may include movements that make the muscles in the neck and back stranger and more flexible. Radiofrequency neurotomy prevents the nerve from sending pain signals to the brain. During chronic lumber disc disease, some things should be avoided smoking, heavy lifting, overdoing it with alcohol, sitting for long periods, and high-impact exercise. Companies and different organizations continually searching for advanced medications for patients.
Download Your Free PDF Sample: Unlock Key Market Insights @ https://cognizancemarketresearch.com/request/chronic-lumber-disc-disease-market/
Global Chronic Lumber Disc Disease Market – Competitive Landscape
On July 24, 2023, Spinal Stabilization Technologies LLC, a leading developer and manufacturer of spinal medical devices, is to be publicly listed through a proposed business combination with BlueRiver Acquisition Corporation. On May 14, 2023, Start-up Gelmetix, the developer of a polymer treatment for chronic lower back pain closed a successful USD 5.4 million series C equity financing round.
Some of the Key Players in the Global Chronic Lumber Disc Disease Market Include –
- Pfizer Inc.
- GlaxoSmithKline Plc.
- Novartis AG
- Mylan N.V.
- Teva Pharmaceutical Industries
- Sanofi
- Boehringer Ingelheim International GmbH
- AstraZeneca
- Medtronic
- Melsungen
- Stryker Corporation
Global Chronic Lumber Disc Disease Market – Growth Drivers
The prevalence rate of chronic lumber disc disease is increasing continuously, according National Center for Biotechnology Information (NCBI), a total of USD 266 million individuals (3.63%) worldwide were found to have DSD and LBP annually. Also, the prevalence rate of obesity increases. According to the Centers for Disease Control and Prevention, the prevalence of obesity was 19.7% and affected about USD 14.7 million children and adolescents. The increasing global aging population contributes significantly to the growth of the chronic lumber disc disease market as age is a primary risk factor for developing this condition. Modern sedentary lifestyles, characterized by prolonged sitting and lack of physical activity, contribute to the rising incidence of chronic lumber disc disease, driving the demand for related treatments. Ongoing advancements in medical technologies, including minimally invasive surgical procedures and innovative diagnostic tools, enhance the treatment options available for chronic lumber disc disease, attracting more patients. Increasing awareness about the symptoms and risk factors of chronic lumber disc disease leads to early diagnosis and treatment, fostering market growth of chronic lumber disc disease through proactive behavior.
Global Chronic Lumber Disc Disease Market – Restraints
Inadequate reimbursement policies for certain chronic lumber disc disease treatments may impede patient access to advanced and expensive interventions, acting as a significant market restraint. Lengthy and stringent regulatory approval processes for new treatments and medical devices can delay market entry, hindering the timely availability of innovative solutions for chronic lumbar disc disease. The high cost associated with surgical procedures, medications, and rehabilitation for chronic lumbar disc disease poses a financial barrier for some patients, limiting the market’s growth potential. According to the National Center for Biotechnology Information (NCBI), the surgical cost of chronic lumber disc disease is approximately USD 11,753 per patient. The availability and popularity of alternative therapies, as well as the inclination towards self-management through home remedies, may divert patients away from conventional medical treatments, impacting market growth. Economic uncertainties, especially in lower-income countries, can restrict healthcare budgets, affecting the adoption of advanced treatments for chronic lumbar disc disease and limiting market expansion. Concerns related to potential complications and side effects associated with certain treatments, particularly surgical interventions, may influence patient and physician preferences, affecting market acceptance. Lack of awareness and education about chronic lumbar disc disease in underserved regions may lead to delayed diagnosis and treatment, hindering the market growth of chronic lumbar disc disease in those areas.
Global Chronic Lumber Disc Disease Market – Opportunities
Opportunities lie in the development of non-invasive and minimally invasive treatment options, offering effective alternatives with fewer complications for patients with chronic lumbar disc disease. Integration of digital health solutions, such as telemedicine and remote monitoring, presents an opportunity to enhance patient care, improve treatment adherence, and expand the reach of chronic lumbar disc disease management globally. Research and development in regenerative medicine, including stem cell therapies and tissue engineering, hold potential for innovative and long-lasting solutions in treating chronic lumbar disc disease. Collaborative efforts between pharmaceutical companies, research institutions, and healthcare organizations can lead to accelerated research and development, bringing novel therapeutic interventions to the market of chronic lumbar disc disease.
Download Free PDF: Sample Our Market Research @ https://cognizancemarketresearch.com/request/chronic-lumber-disc-disease-market/
Global Chronic Lumber Disc Disease Market – Geographical Insight
The market for global chronic disc disease is segmented into regions such as North America, Latin America, Europe, Asia-Pacific, the Middle East & Africa. North America is the largest market for global chronic lumbar disc disease due to the high prevalence of chronic lumbar disc disease. Advanced healthcare infrastructure with easy access to innovative treatments. Europe has significant cases of chronic lumbar disc disease, especially healthcare systems support the adoption of advanced treatments. The regulatory framework contributes to stringent approval processes for new interventions. Asia-Pacific regions have increasing prevalence due to lifestyle changes and aging populations. Varied healthcare landscapes, with developed markets like Japan and emerging markets with evolving healthcare infrastructure.
Global Chronic Lumber Disc Disease Market – Key Developments
- September 28, 2023, the FDA approved IDE for ReGelTec’s pivotal study of HYDRAFIL® for chronic low back pain due to generative disc disease.
- On September 13, 2023, MarinHealth launched the new MarinHealth Spine Institute, the region’s most comprehensive spine care program.
- On February 10, 2021, a Mesoblast phase 3 trial showed that a single injection of Rexlemestrocel-L + Hyaluronic Acid carrier results in at least two years of pain reduction with opioid-sparing activity in patients with chronic low back pain due to degenerative disc disease.